APO Research
Talk to an analyst

APO RESEARCH · REPORT

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Analysis and Forecast 2026-2032

1 January 2026194 pages

Choose your research edition.

Industry ResearchGranulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs include Teva, Novartis, Merck, Pfizer, Amgen, SL Pharm, North China Pharmaceutical, Kyowa Kirin and Intas, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs revenue, projected growth trends, production technology, application and end-user industry.

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Company

Teva

Novartis

Merck

Pfizer

Amgen

SL Pharm

North China Pharmaceutical

Kyowa Kirin

Intas

Hayao Group

GenSci

Dr. Reddy

Dong-A Socio

Chugai Pharmaceutical

Amoytop

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Type

Filgrastim

Lipefigrastim

Pefigrastim

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Application

Oncology

Blood Disease

Other

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Granulocyte-Colony Stimulating Factor (G-CSF) Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Filgrastim Major Player Table 3. Lipefigrastim Major Player Table 4. Pefigrastim Major Player Table 5. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Oncology Major Player Table 7. Blood Disease Major Player Table 8. Other Major Player Table 9. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Trends Table 10. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Drivers Table 11. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Opportunities and Challenges Table 12. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Restraints Table 13. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Region (2021-2026) Table 16. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Region (2027-2032) Table 18. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Players (2021-2026) Table 20. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Key Players Headquarters & Area Served Table 22. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players, Product Type & Application Table 23. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Type (2027-2032) Table 31. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Application (2021-2026) Table 35. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Application (2027-2032) Table 36. Teva Company Information Table 37. Teva Business Overview Table 38. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 40. Teva Recent Development Table 41. Novartis Company Information Table 42. Novartis Business Overview Table 43. Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 45. Novartis Recent Development Table 46. Merck Company Information Table 47. Merck Business Overview Table 48. Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 50. Merck Recent Development Table 51. Pfizer Company Information Table 52. Pfizer Business Overview Table 53. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 55. Pfizer Recent Development Table 56. Amgen Company Information Table 57. Amgen Business Overview Table 58. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 60. Amgen Recent Development Table 61. SL Pharm Company Information Table 62. SL Pharm Business Overview Table 63. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 65. SL Pharm Recent Development Table 66. North China Pharmaceutical Company Information Table 67. North China Pharmaceutical Business Overview Table 68. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 70. North China Pharmaceutical Recent Development Table 71. Kyowa Kirin Company Information Table 72. Kyowa Kirin Business Overview Table 73. Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 75. Kyowa Kirin Recent Development Table 76. Intas Company Information Table 77. Intas Business Overview Table 78. Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 80. Intas Recent Development Table 81. Hayao Group Company Information Table 82. Hayao Group Business Overview Table 83. Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 85. Hayao Group Recent Development Table 86. GenSci Company Information Table 87. GenSci Business Overview Table 88. GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 90. GenSci Recent Development Table 91. Dr. Reddy Company Information Table 92. Dr. Reddy Business Overview Table 93. Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 95. Dr. Reddy Recent Development Table 96. Dong-A Socio Company Information Table 97. Dong-A Socio Business Overview Table 98. Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 100. Dong-A Socio Recent Development Table 101. Chugai Pharmaceutical Company Information Table 102. Chugai Pharmaceutical Business Overview Table 103. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 105. Chugai Pharmaceutical Recent Development Table 106. Amoytop Company Information Table 107. Amoytop Business Overview Table 108. Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 110. Amoytop Recent Development Table 111. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 112. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 113. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 114. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 115. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 117. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (US$ Million) & (2027-2032) Table 118. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 119. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 120. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 121. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 122. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 123. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 124. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (US$ Million) & (2027-2032) Table 125. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 126. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 127. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 128. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 129. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 130. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 131. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 132. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 133. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Region (US$ Million) & (2021-2026) Table 135. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Region (US$ Million) & (2027-2032) Table 136. SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 137. SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 138. SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 139. SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 140. SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 142. SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (US$ Million) & (2027-2032) Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Image Figure 2. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Filgrastim Image Figure 5. Lipefigrastim Image Figure 6. Pefigrastim Image Figure 7. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Oncology Image Figure 10. Blood Disease Image Figure 11. Other Image Figure 12. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (US$ Million) & (2021-2032) Figure 13. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Type (2021-2032) Figure 20. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Application (2021-2032) Figure 23. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Type (2021-2032) Figure 25. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Application (2021-2032) Figure 26. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Country (2021-2032) Figure 27. United States Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Type (2021-2032) Figure 32. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Application (2021-2032) Figure 33. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Country (2021-2032) Figure 34. Germany Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Type (2021-2032) Figure 44. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Application (2021-2032) Figure 45. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Type (2021-2032) Figure 47. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Application (2021-2032) Figure 48. Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Region (2021-2032) Figure 49. Japan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Type (2021-2032) Figure 57. SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Application (2021-2032) Figure 58. SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Country (2021-2032) Figure 59. Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Filgrastim
  • Lipefigrastim
  • Pefigrastim
Applications
  • Oncology
  • Blood Disease
  • Other
Companies covered
  • Teva
  • Novartis
  • Merck
  • Pfizer
  • Amgen
  • SL Pharm
  • North China Pharmaceutical
  • Kyowa Kirin
  • Intas
  • Hayao Group
  • GenSci
  • Dr. Reddy
  • Dong-A Socio
  • Chugai Pharmaceutical
  • Amoytop

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Type
  3. 1.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Filgrastim
  5. 1.2.3 Lipefigrastim
  6. 1.2.4 Pefigrastim
  7. 1.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Application
  8. 1.3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Oncology
  10. 1.3.3 Blood Disease
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Dynamics
  1. 2.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Trends
  2. 2.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Drivers
  3. 2.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Opportunities and Challenges
  4. 2.4 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Perspective (2021-2032)
  2. 3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Growth Trends by Region
  3. 3.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Players
  2. 4.1.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players, Product Type & Application
  8. 4.5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market CR5 and HHI
  11. 4.6.3 2025 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Tier 1, Tier 2, and Tier 3
5 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type
  1. 5.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Type (2021-2032)
6 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application
  1. 6.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva
  2. 7.1.1 Teva Company Information
  3. 7.1.2 Teva Business Overview
  4. 7.1.3 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  6. 7.1.5 Teva Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Merck
  14. 7.3.1 Merck Company Information
  15. 7.3.2 Merck Business Overview
  16. 7.3.3 Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  18. 7.3.5 Merck Recent Developments
  19. 7.4 Pfizer
  20. 7.4.1 Pfizer Company Information
  21. 7.4.2 Pfizer Business Overview
  22. 7.4.3 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  24. 7.4.5 Pfizer Recent Developments
  25. 7.5 Amgen
  26. 7.5.1 Amgen Company Information
  27. 7.5.2 Amgen Business Overview
  28. 7.5.3 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  30. 7.5.5 Amgen Recent Developments
  31. 7.6 SL Pharm
  32. 7.6.1 SL Pharm Company Information
  33. 7.6.2 SL Pharm Business Overview
  34. 7.6.3 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  36. 7.6.5 SL Pharm Recent Developments
  37. 7.7 North China Pharmaceutical
  38. 7.7.1 North China Pharmaceutical Company Information
  39. 7.7.2 North China Pharmaceutical Business Overview
  40. 7.7.3 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  42. 7.7.5 North China Pharmaceutical Recent Developments
  43. 7.8 Kyowa Kirin
  44. 7.8.1 Kyowa Kirin Company Information
  45. 7.8.2 Kyowa Kirin Business Overview
  46. 7.8.3 Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  48. 7.8.5 Kyowa Kirin Recent Developments
  49. 7.9 Intas
  50. 7.9.1 Intas Company Information
  51. 7.9.2 Intas Business Overview
  52. 7.9.3 Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  54. 7.9.5 Intas Recent Developments
  55. 7.10 Hayao Group
  56. 7.10.1 Hayao Group Company Information
  57. 7.10.2 Hayao Group Business Overview
  58. 7.10.3 Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  60. 7.10.5 Hayao Group Recent Developments
  61. 7.11 GenSci
  62. 7.11.1 GenSci Company Information
  63. 7.11.2 GenSci Business Overview
  64. 7.11.3 GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  66. 7.11.5 GenSci Recent Developments
  67. 7.12 Dr. Reddy
  68. 7.12.1 Dr. Reddy Company Information
  69. 7.12.2 Dr. Reddy Business Overview
  70. 7.12.3 Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  72. 7.12.5 Dr. Reddy Recent Developments
  73. 7.13 Dong-A Socio
  74. 7.13.1 Dong-A Socio Company Information
  75. 7.13.2 Dong-A Socio Business Overview
  76. 7.13.3 Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  78. 7.13.5 Dong-A Socio Recent Developments
  79. 7.14 Chugai Pharmaceutical
  80. 7.14.1 Chugai Pharmaceutical Company Information
  81. 7.14.2 Chugai Pharmaceutical Business Overview
  82. 7.14.3 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  84. 7.14.5 Chugai Pharmaceutical Recent Developments
  85. 7.15 Amoytop
  86. 7.15.1 Amoytop Company Information
  87. 7.15.2 Amoytop Business Overview
  88. 7.15.3 Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  90. 7.15.5 Amoytop Recent Developments
8 North America
  1. 8.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (2021-2032)
  2. 8.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country
  11. 8.6.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (2021-2032)
  2. 9.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country
  11. 9.6.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (2021-2032)
  2. 10.2 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2027-2032)
  5. 10.3 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2027-2032)
  9. 10.5 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (2021-2032)
  2. 11.2 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country
  11. 11.6.1 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country
  11. 12.6.1 SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst